BPC-157 for Gut Health: What Rats Have Shown, What Humans Have Not, and What Actually Treats Each Gut Problem

Written by Dr. Andrii Kaleniuk. Updated October 28, 2026.

BPC-157 for gut health is the one use of the peptide where the animal evidence is deep rather than scattered, and the one where it comes closest to making biological sense: the molecule was isolated from human gastric juice, it is stable in stomach acid, and in rats it has healed ulcers caused by NSAIDs and alcohol, repaired inflamed colon, closed fistulas, protected the oesophagus from reflux and improved survival after massive bowel resection. That is also where the evidence stops. In humans there is one Phase II trial in ulcerative colitis from 2005 that was never published as a paper, a handful of Phase I safety studies, and no randomised trial of any gut condition since. Nothing sold today as BPC-157 is a medicine, the FDA considers it unapproved and has blocked its compounding, and the people buying it for 'leaky gut', IBS or Crohn's are treating conditions that have approved, tested therapies. This review sets out, condition by condition, what rats have shown and what humans have not, explains why the gut data do not transfer to the systemic claims, and lists the treatments that actually exist for each gut problem BPC-157 is marketed for.

BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice, first described by Predrag Sikiric's group in Zagreb in the early 1990s and named 'body protection compound' for its apparent ability to protect the stomach lining in rats. Two facts make the gut a special case. The peptide is unusually stable in gastric acid, surviving for hours where most peptides are broken down in minutes, which is why oral dosing in rats produces gut effects. And the gut lining is where an oral dose actually goes: whatever its systemic absorption, which has never been measured in humans, a swallowed peptide bathes the stomach, small intestine and colon directly. That is a far more plausible route to a local effect than the claim that a capsule heals a shoulder tendon. The oral absorption question, and why it matters for every non-gut claim, is covered in oral BPC-157. The flip side is that strong local gut data in rats say nothing about whether the peptide does anything once it enters the bloodstream, which is the basis of every other use.

The animal literature on BPC-157 and the gut is large, consistent and almost entirely from one group, which is both its strength and its limitation. The table lists the main models and what was found; nearly all used injected or drinking-water doses far above anything a capsule would deliver, and nearly all compared against untreated controls rather than against an existing drug.

In the early 2000s a Croatian company, Pliva, developed BPC-157 under the code PL-14736 and ran Phase I safety studies and a Phase II trial in ulcerative colitis. The Phase II result appeared as a conference abstract in 2005 and has been cited ever since as evidence that BPC-157 'passed human trials'. It did not, in the sense that matters: the full data, the dose, the comparator, the primary endpoint and the effect size were never published in a peer-reviewed journal, the programme was dropped, and no company has picked it up in the twenty years since. Pharmaceutical development is not sentimental; a peptide that showed a clear effect in colitis in 2005 would have been pursued, because ulcerative colitis drugs are among the most valuable in medicine. The most reasonable reading of silence is that the effect, if any, was not large enough to justify Phase III. The Phase I studies, by intravenous and rectal routes, found the peptide well tolerated at the doses used, which is useful as far as it goes and is the only human safety data that exists; it is discussed alongside the animal toxicology in BPC-157 side effects.

Because BPC-157 is not an approved drug and, since the FDA's April 2026 decision, cannot be legally compounded either, every product sold as BPC-157 for gut health falls into one of three categories: a 'research chemical' vial from a peptide vendor, a capsule marketed as a supplement in defiance of the rules on unapproved drugs, or a compounded product from a pharmacy that is ignoring the FDA. None are tested for content by any regulator, the FDA's own testing of similar peptide products has found wrong amounts and contaminants, and the 'arginate salt' capsules sold as better absorbed rest on patent claims and a rat study, not human data. The regulatory position, including the July 2026 advisory vote that could eventually reopen compounding, is tracked in is BPC-157 legal. The point for someone with a gut problem is simple: whatever the rats show, the thing in the bottle has not been shown to be BPC-157 at the stated dose, and no human dose for any gut condition has ever been established.

Each gut problem BPC-157 is sold for has therapies with human trial data, and the comparison is not close. NSAID-related ulcers respond to proton-pump inhibitors in a matter of weeks and are prevented by co-prescribing one; reflux has the same drugs plus surgery for refractory cases. Ulcerative colitis and Crohn's disease have a ladder of treatments from mesalamine through steroids to biologics and JAK inhibitors, with remission rates measured in thousands of patients. Short bowel syndrome has teduglutide, a GLP-2 analogue that increases absorption and has done in humans what BPC-157 has done in rats. IBS has dietary therapy, antispasmodics, rifaximin and gut-directed neuromodulators, each with randomised trials. A person with persistent gut symptoms who is weighing an unregulated peptide against these is not choosing between two options of unknown value; they are choosing between tested treatments and an untested one. Where BPC-157 might one day fit is as an adjunct, if a company ever runs the trial, and nothing in the current evidence says that day is close.

It is worth being clear that the gut is BPC-157's best case, not its typical one. For tendon, ligament and muscle injury, the uses that dominate online discussion, the evidence is also rat-only but with a weaker mechanism, because a swallowed peptide must survive digestion, cross the gut wall, circulate and reach a tendon in meaningful amounts, none of which has been shown. The tendon claims are examined in BPC-157 for tendon recovery and BPC-157 for shoulder pain, and the combination products in BPC-157 vs TB-500 and the Wolverine stack. If someone is going to argue that BPC-157 does anything in humans, the gut is where the argument should start; that the argument has not been won even there is the most informative fact in this whole field.

BPC-157 has healed just about every kind of gut injury that can be induced in a rat, which is more than can be said for most of its other claims, and the biology of an acid-stable peptide acting on the gut lining is not far-fetched. But thirty years on, the human evidence is one unpublished Phase II trial from 2005 and nothing since, the FDA regards it as an unapproved drug, no human dose exists, and the products sold are untested. Every gut condition it is marketed for has treatments that have passed the trials BPC-157 has not. For gut health, BPC-157 is an interesting rat result waiting for a company willing to test it in people; it is not a treatment.

This review summarizes published animal and human research and regulatory records for general information. BPC-157 is not an approved treatment for any condition; gut symptoms should be evaluated by a clinician.